MRSA: KIMYRSA (oritavancin) receives FDA approval for treatment of ABSSSI
by Press Release from Outbreak News Today on (#5FCD2)
Melinta Therapeutics, LLC (Melinta), today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSATM (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). KIMYRSA is a lipoglycopeptide antibiotic that delivers a complete course [...]
The post MRSA: KIMYRSA (oritavancin) receives FDA approval for treatment of ABSSSI appeared first on Outbreak News Today.